FACULTY
Cody A. Parsons, APh, PharmD, BCCCP
Director of Clinical Operations
Cardiovascular Health
Stanford Health Care
Stanford, California
Nosheen Reza, MD, FACC, FHFSA
Assistant Professor of Medicine
Penn Center for Inherited Cardiovascular Disease
Section of Heart Failure, Transplantation
and Mechanical Support
Penn Medicine
Philadelphia, Pennsylvania
PROGRAM OVERVIEW
This Expert Dialogue Program is designed to enhance pharmacists’ understanding of the interplay between hypertension and atrial fibrillation (AFib) and its impact on heart failure with preserved ejection fraction (HFpEF) risk. Led by a pharmacist and cardiologist, the program combines didactic and case-based learning, including a video case study, to explore the evolving landscape of AFib screening and early detection, with emphasis on emerging technologies that can improve identification of at-risk patients in real-world settings. Faculty will highlight pulse pressure waveform (PPW) technology and other innovative screening approaches that may support earlier detection and ongoing monitoring of AFib in patients with or without hypertension. The activity will also provide practical strategies for shared decision making, personalized care planning, and use of point-of-care tools.
TARGET AUDIENCE
This activity is designed to meet the educational needs of pharmacists involved in the screening and management of patients with or at risk for hypertension (HTN) and atrial fibrillation (AFib).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the link between HTN and AFib and their shared contribution to the risk of HFpEF
- Appraise novel and emerging screening tools, including clinically validated pulse pressure waveform (PPW) technology, and their utility in the early detection and monitoring of AFib
- Apply evidence-based strategies in pharmacy setting to appropriately screen patients with HTN and others at risk for AFib
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of up to 1.0 knowledge-based CPE contact hour.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Cody A. Parsons, APh, PharmD, BCCCP | Consultant | Hikma Pharmaceuticals, Long Grove Pharmaceuticals |
| Nosheen Reza, MD, FACC, FHFSA |
Consultant | Novo Nordisk, Roche, Bristol Myers Squibb, Cytokinetics |
| Contracted research | Bristol Myers Squibb |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Dominique Barton, B.S., BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Nicholas Torres, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 30, 2026
EXPIRATION DATE: October 30, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
